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study was shown to be superior to those of Celecoxib for treating active
osteoarthritis.
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A PILOT STUDY OF THE USE OF A TRUFIT PLUG FOR CARTILAGE REPAIR
IN THE KNEE AND HOW TO DEAL WITH EARLY CLINICAL FAILURES?
A.A. Dhollander, K. Liekens, F. Almqvist, R. Verdonk, S. Lambrecht,
D. Elewaut, G. Verbruggen, P.C. Verdonk. Ghent Univ., Ghent, Belgium
Purpose: The purpose of this pilot study is to present our short-term
experience with the TruFit plug (Smith & Nephew, Andover, MA) for
cartilage repair in the knee and to discuss our approach to treat early
clinical failures.
Methods: Twenty patients were consecutively treated for their cartilage
lesion with this plug technique. These patients were prospectively
clinically evaluated at 6 and 12 months of follow-up. Magnetic resonance
imaging (MRI) was used for morphological analysis of the cartilage repair.
Biopsy samples were taken from 3 cases during revision surgery, allowing
histological assesment of the repair tissue.
Results: The short-term clinical and MRI outcome of this pilot study
are mediocre. No signs of deterioration of the repair tissue were
observed. Three of the 15 patients (20.0%) displayed persistent or even
more clinical symptoms after insertion of the plug. These patients
were considered as failures and therefore eligible for revision surgery.
During revision surgery the repair tissue was carefully removed. The
remaining osteochondral defect was ﬁlled with autologous bone grafts.
Immediate and persistent relieve of symptoms was observed in all
3 patients. Histological assessment of biopsy specimens taken during
revision surgery of these 3 patients revealed ﬁbrous vascularized repair
tissue with the presence of foreign-body giant cells.
Conclusion: The overall short term clinical and MRI outcome of a
TruFit plug for cartilage repair in the knee is mediocre. In this pilot
study a modest clinical improvement became apparent at 12 months
of follow-up. MRI data showed no deterioration of the repair tissue.
Remarkably, 3 of the 15 patients (20%) had persistent clinical symptoms
after surgery. These patients were succesfully treated with the removal
of the osteochondral plug remnants and the application of autologous
bone grafts. Longer follow-up studies and randomised controlled trials
are mandatory to conﬁrm the ﬁndings of this pilot study.
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Purpose: The purpose of this paper was to present our mid-term
experience with the implantation of alginate beads containing human
mature allogenic chondrocytes for the treatment of cartilage lesions in
the knee.
Methods: A biodegradable, alginate-based biocompatible scaffold
containing human mature allogenic chondrocytes was used for cartilage
lesions in the knee. Twenty-one patients were clinically prospectively
evaluated with use of the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) and a Visual Analogue Scale (VAS). The
mean follow-up time was 6.3 years (5–8 years). MRI data were analyzed
based on the MOCART (Magnetic Resonance Observation of Cartilage
Repair Tissue) system, allowing morphological assessment of the repair
tissue. MRI images were taken at one year of follow-up and at a mean
follow-up of 6.1 years (5–7 years).
Results: During the follow-up period the WOMAC and VAS scores
improved signiﬁcantly. No signs of clinical deterioration or adverse
reactions to the alginate beads/allogenic chondrocyte implantation were
observed. Four failures occured during the follow-up period in this study
(19.05%). The MOCART scoring methods indicated that the condition of
the repair tissue deteriorated on MRI.
Conclusions: This investigation provided useful information on the
efﬁcacy of this new treatment in chondral lesions of the knee. The
mid-term clinical outcome of the presented technique was promising.
However, these results were not conﬁrmed by the MRI ﬁndings.
Moreover, the MRI data indicated a deterioration of the repair tissue.
These results inspire us to search for further improvements of this
technique.
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DULOXETINE AS TREATMENT FOR KNEE PAIN IN PATIENTS
WITH OSTEOARTHRITIS WHO REGULARLY USE NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS (NSAIDs): A POST HOC ANALYSIS OF
TWO RANDOMIZED, PLACEBO-CONTROLLED TRIALS
M.C. Hochberg1, L. Peng2, J. Ahl2, S. Zhang3, V. Skljarevski3, P. Gaynor2,
M.M. Wohlreich2. 1Univ. of Maryland Sch. of Med., Baltimore, MD, USA;
2Lilly USA, LLC, Indianapolis, IN, USA; 3Lilly Res. Lab., Eli Lilly and Company,
Indianapolis, IN, USA
Purpose: To examine whether treatment with duloxetine has similar
efﬁcacy in patients with symptomatic knee osteoarthritis (OA) who
regularly use NSAIDs as compared with those who do not.
Methods: We conducted a post hoc analysis of data from 2 randomized,
placebo-controlled trials of duloxetine in patients with symptomatic
knee OA. In each trial, patients were randomized to 13 weeks of
treatment with duloxetine 60–120mg once daily or placebo, and
stratiﬁed according to concomitant NSAID use at baseline. NSAID users
were identiﬁed as those patients who were taking a therapeutic dose
of NSAID or acetaminophen for ≥14 days per month for 3 months
immediately preceding the study. Efﬁcacy measures were the Brief
Pain Inventory (BPI) 24-h average pain severity score (0–10), and
the Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC;0–96). Missing data were imputed using last-observation-
carried-forward method. Differences in treatment effect of duloxetine
versus placebo between subgroups were analyzed with an ANCOVA
model that included therapy, study, baseline value, concomitant NSAID
use, and therapy-by-NSAID subgroup interaction. Safety and tolerability
were assessed with spontaneously reported treatment-emergent adverse
events (TEAEs).
Results: There were a total of 105 duloxetine NSAID users, 112
placebo NSAID users, 134 duloxetine non-NSAID users, and 136 placebo
non-NSAID users. Overall mean baseline ratings were BPI average
pain=6.15, and WOMAC total=51.37, and there were no signiﬁcant
differences between NSAID subgroups on these measures. Mean changes
from baseline are summarized in Figure 1. Treatment-by-NSAID use
interactions were not signiﬁcant for either of the outcome measures,
which suggests that the effect of duloxetine treatment was not affected
by concomitant NSAID use. Nausea was the most common TEAE reported
in patients treated with duloxetine vs. placebo that was signiﬁcantly
(p < 0.05) more frequent regardless of concomitant NSAID use. In addition
among NSAID users, patients treated with duloxetine vs. placebo reported
signiﬁcantly more hyperhidrosis (p < 0.05); and constipation (p < 0.01)
was reported signiﬁcantly more frequently among the non-NSAID users.
Fig. 1. Mean changes from baseline in BPI average pain severity and
WOMAC total.
Conclusions: There were a total of 105 duloxetine NSAID users, 112
placebo NSAID users, 134 duloxetine non-NSAID users, and 136 placebo
non-NSAID users. Overall mean baseline ratings were BPI average
pain=6.15, and WOMAC total=51.37, and there were no signiﬁcant
differences between NSAID subgroups on these measures. Mean changes
from baseline are summarized in Figure 1. Treatment-by-NSAID use
interactions were not signiﬁcant for either of the outcome measures,
which suggests that the effect of duloxetine treatment was not affected
by concomitant NSAID use. Nausea was the most common TEAE reported
